Jump Financial LLC Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Jump Financial LLC reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 34.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 201,227 shares of the biopharmaceutical company's stock after selling 105,944 shares during the quarter. Jump Financial LLC owned about 0.07% of Amicus Therapeutics worth $1,896,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of FOLD. Covestor Ltd boosted its holdings in shares of Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 2,312 shares during the period. R Squared Ltd acquired a new stake in shares of Amicus Therapeutics during the 4th quarter valued at $79,000. Virtu Financial LLC bought a new position in Amicus Therapeutics during the 3rd quarter worth $107,000. KBC Group NV raised its position in Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 3,120 shares during the last quarter. Finally, Sciencast Management LP bought a new position in Amicus Therapeutics during the 4th quarter worth $100,000.

Amicus Therapeutics Price Performance

Shares of FOLD traded up $0.01 during mid-day trading on Thursday, reaching $7.11. The stock had a trading volume of 1,041,320 shares, compared to its average volume of 2,603,307. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -39.58, a PEG ratio of 1.51 and a beta of 0.79. Amicus Therapeutics, Inc. has a 12 month low of $6.20 and a 12 month high of $12.65. The business has a fifty day moving average of $8.26 and a 200 day moving average of $9.44. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.

Analyst Ratings Changes

A number of analysts recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, February 20th. Wells Fargo & Company decreased their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.